The Beauty Health Company reported a decline in financial performance for the third quarter of 2025, with net sales totaling $70.7 million, a decrease of 10.3% from $78.8 million in the same period last year. The company's net loss for the quarter was $11.0 million, compared to a loss of $18.3 million in the prior year. The decrease in revenue was primarily attributed to a significant drop in sales of Delivery Systems, which fell by 24.6% to $20.8 million, while Consumables sales decreased slightly by 2.6% to $49.8 million. The company noted that unfavorable macroeconomic conditions and a transition in the China market to a distributor partner negatively impacted sales.
In terms of profitability, the company's gross profit increased to $45.6 million, up from $40.6 million, resulting in a gross margin improvement to 64.6% from 51.6%. This increase was driven by lower inventory-related charges and a favorable shift towards higher-margin consumable sales. Operating expenses also decreased significantly, totaling $51.9 million compared to $62.2 million in the previous year, primarily due to reduced selling and marketing costs and lower personnel-related expenses.
The Beauty Health Company has made strategic moves to enhance its operational efficiency, including the appointment of new leadership in key roles and the implementation of enhanced training and operational guidelines. These changes are part of a broader effort to address a material weakness in internal controls related to inventory management. The company is optimistic about its ability to improve operational performance and is currently focused on executing its business plan, which includes expanding its product offerings and market reach.
As of September 30, 2025, the company reported total assets of $503.6 million, down from $685.7 million at the end of 2024, with cash and cash equivalents decreasing to $219.4 million. The company’s total liabilities also decreased to $438.0 million from $633.9 million, largely due to the repurchase of convertible senior notes. The company’s outlook remains cautious, as it continues to navigate macroeconomic challenges, including inflation and potential recessionary impacts on consumer spending.
Looking ahead, The Beauty Health Company aims to leverage its strong brand portfolio, including Hydrafacial and SkinStylus, to drive growth. The company is also exploring potential acquisitions to enhance its product offerings and market presence. However, it acknowledges that ongoing economic uncertainties may pose risks to its revenue and operational performance in the near term.
About Beauty Health Co
The Beauty Health Company designs, manufactures, and markets esthetic medical devices and consumables focused on skin and scalp health. Its flagship Hydrafacial brand offers patented hydradermabrasion treatments via proprietary Delivery Systems and consumables, supported by complementary brands SkinStylus (microneedling) and Keravive (scalp care). Serving professional medical providers and estheticians globally, the company employs a razor-and-blades business model, leveraging a community-driven platform to deliver personalized, non-invasive beauty health experiences.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.